Aadi Bioscience : Corporate Overview

Corporate Overview

March 2022

© 2022

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934 as amended, and the Private Securities Litigation Act

of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Aadi Bioscience, Inc. ("Aadi") undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," "aims," and similar expressions to

identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Aadi's plans to develop and commercialize its product candidates, including FYARRO™ (nab-sirolimus,ABI-009); Aadi's commercialization, marketing and manufacturing capabilities and strategy; the clinical utility, potential benefits and market acceptance of FYARRO and any other of Aadi's product candidates; risks related to the sufficiency Aadi's cash balance to fund

operations; the timing of initiation of Aadi's planned clinical trials; the timing of the availability of data from Aadi's clinical trials; Aadi's plans to research, develop and commercialize its current and future product candidates; Aadi's ability to successfully enter into collaborations, and to fulfill its obligations under any such collaboration agreements; Aadi's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Aadi's competitors and our its industry; the impact of government laws and regulations; Aadi's ability to protect its intellectual property position; the impact of the COVID-19 pandemic on Aadi's operations, the biotechnology industry and the economy generally and Aadi's estimates regarding future revenue, expenses, capital requirements and need for additional financing.

These risks are described in detail under the caption "Risk Factors" in Aadi's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission (the "SEC") on November 10, 2021, and other documents filed from time to time with the SEC. Forward-looking statements included in this presentation are based on information available to Aadi as of the date of this presentation. Aadi undertakes any obligation to such forward-looking statements to reflect events or circumstances after the date of this presentation.

© 2022	2

FYARRO Commercially Available and NCCN Listed as Preferred Regimen

Now Commercially

Available!

First and only therapy approved to treat locally advanced unresectable or metastatic malignant PEComa

Albumin-boundmTOR inhibitor leveraging nab-technology to deliver a favorable clinical profile in an area of high unmet medical need

Efficacy defined by ORR and DOR with an adverse event profile that is

predictable and manageable

Included in NCCN Guidelines as the only 'Preferred' treatment for

malignant PEComa

© 2022	3

Aadi Bioscience is a Commercial-Stage, Precision Oncology Company Re-engineering mTOR Inhibition

• Commercial stage biotech company striving to unleash the potential of mTOR inhibition using proven nanoparticle albumin technology in cancers with mTOR pathway driver alterations
• Focused on the commercialization of FYARROTM (sirolimus protein-bound particles for injectable suspension [albumin-bound],nab-sirolimus), an albumin-bound mTOR inhibitor developed using the validated nanoparticle albumin-based (nab) platform proven with ABRAXANE®

NASDAQ: AADI

• PRECISION 1 registrational study pursuing a significant potential opportunity in tumor-agnosticTSC1 or TSC2 inactivating alterations in solid tumors now open for enrollment
• Funded by leading healthcare investors with cash runway projected into 2024 to support commercialization and future clinical development of FYARRO

© 2022	4

Leadership: We are Building a World-Class Team with Deep Expertise in Oncology Commercialization and Development

Neil Desai, PhD

Founder, CEO

and President

• Former Sr VP, Global R&D at Abraxis Bioscience
• Previously Vice President, Strategic Platforms, Celgene; prior positions of increasing seniority at American
  BioScience, Inc.
• Inventor of the nab technology (Abraxane and ABI-009)
• 25+ years in R&D

Brendan Delaney, MBA	Scott Giacobello, CPA	Loretta Itri, MD
Chief Operating Officer	Chief Financial Officer	Chief Medical Officer
• Previously CCO at	• Previously CFO GW	• Previously CMO at
Constellation Pharma	Pharmaceuticals	Immunomedics
(acquired by MorphSys)	• Former CFO Chase	• Former EVP Global Health
• Former CCO at
Pharmaceutical Corp.;	Sciences & Regulatory
Immunomedics (acquired by	EVP&CFO VIZI Health	Affairs, The Medicines
Gilead); VP of US	Solutions; VP Finance-Global	Company; President,
Hematology /Oncology at	R&D Allergan as well as VP	Pharmaceutical
Celgene	Corporate Finance and VP	Development, CMO Genta,
• 25+ years commercial	Finance - Audit and	Inc.; SVP, WW Clinical Affairs
Compliance	at Johnson & Johnson,
experience including prior	• 13+ years pharmaceutical	Ortho Biotech
roles at Novartis Oncology	• 40+ years drug development
and Genentech	finance experience
		experience

Mitchall Clark,

BPharm, MRPharmS

SVP Regulatory Affairs and

Quality Assurance

• Previously Chief Regulatory / Quality Officer, Atara Biotherapeutics
• Former SVP Regulatory Affairs at Abraxis Bioscience
• Worldwide regulatory experience with Abraxane; 25+ years in regulatory affairs

Stephen Rodin, JD

SVP / General Counsel

• Previously EVP / General Counsel at The Medicines Company (acquired by Novartis)
• Led or played a substantial role in $750M+ acquisitions and $650M+ of divestitures during 13-year tenure with The Medicines Company
• 15 years pharmaceutical legal experience

© 2022	5